SEARCH

SEARCH BY CITATION

References

  • 1
    Afdhal NH, Geahigan T. Supporting the patient with chronic hepatitis during treatment. In: KoffRS, WuGY, ed. Clinical Gastroenterology: Diagnosis and Therapeutics. Totowa, NJ: Humana Press, 211232.
  • 2
    Maddrey WC. Safety of combination interferon alfa-2b/ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Semin Liver Dis 1999; 19 (Suppl 1): 6775.
  • 3
    McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin Liver Dis. 1999; 19 (Suppl 1): 5765.
  • 4
    Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 14261432.
  • 5
    Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, Salfi M, et al. Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group. Clin Pharmacol Ther 2000; 68: 556567.
  • 6
    Zeuzem S, Heathcote JE, Martin N, Nieforth K, Modi M. Peginterferon alfa-2a (40 kDa) monotherapy: a novel agent for chronic hepatitis C therapy. Expert Opin Investig Drugs 2001; 10: 22012213.
  • 7
    Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958965.
  • 8
    Fried MW, Shiffmann ML, Reddy R, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975982.
  • 9
    McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 14851492.
  • 10
    Jain K, Lam WC, Waheeb S, Thai Q, Heathcote J. Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. Br J Ophthalmol 2001; 85: 11711173.
  • 11
    Hejny C, Sternberg P, Lawson DH, Greiner K, Aaberg TM Jr. Retinopathy associated with high-dose interferon alfa-2b therapy. Am J Ophthalmol 2001; 131: 782787.
  • 12
    Nadir A, Amin A, Chalisa N, van Thiel DH. Retinal vein thrombosis associated with chronic hepatitis C: a case series and review of the literature. J Viral Hepat 2000; 7: 466470.
  • 13
    Cadoni G, Marinelli L, De Santis A, Romito A, Manna R, Ottaviani F. Sudden hearing loss in a patient hepatitis C virus (HCV) positive on therapy with alpha-interferon: a possible autoimmune-microvascular pathogenesis. J Laryngol Otol 1998; 112: 962963.
  • 14
    Karim A, Ahmed S, Khan A, Steinberg H, Mattana J. Interstitial pneumonitis in a patient treated with alpha-interferon and ribavirin for hepatitis C infection. Am J Med Sci 2001; 322: 233235.
  • 15
    Chin K, Tabata C, Sataka N, Nagai S, Moriyasu F, Kuno K. Pneumonitis associated with natural and recombinant interferon alfa therapy for chronic hepatitis C. Chest 1994; 105: 939941.
  • 16
    Boonyapisit K, Katirji B. Severe exacerbation of hepatitis C-associated vasculitic neuropathy following treatment with interferon alpha: a case report and literature review. Muscle Nerve 2002; 25: 909913.
  • 17
    Li SD, Yong S, Srinivas D, Van T. Reactivation of sarcoidosis during interferon therapy. J Gastroenterol 2002; 37: 5054.
  • 18
    Teragawa H, Hondo T, Amano H, Hino F, Ohbayashi M. Adverse effects of interferon on the cardiovascular system in patients with chronic hepatitis C. Jpn Heart 1996; 37: 905915.
  • 19
    Fujiwara T, Kiura K, Ochi K, Matsubara H, Yamanari H, Shimomura H, Harada M. Giant negative T waves during interferon therapy in a patient with chronic hepatitis C. Intern Med 2001; 40: 105109.
  • 20
    Ferenci P, Shiffman ML, Fried MW, Sulkowski MS, Haeussinger D, Zarski J-P, Goncales FL, et al. Early prediction of response to 40KDA peginterferon alfa-2a (PEGASYS) plus ribavirin in patients with chronic hepatitis C [Abstract]. Hepatology 2001; 34: 351A.
  • 21
    McHutchison JG, Manns MP, Patel K, Poynard T, Lindsay KL, Trepo C, Dienstag J, et al. Adherence to combination therapy enhances sustained response in genotype-1 infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 10611069.
  • 22
    De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, Noventa F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000; 31: 9971004.
  • 23
    Neary MP, Cort S, Bayliss MS, Ware JE Jr. Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Semin Liver Dis 1999; 19 (Suppl 1): 7785.
  • 24
    Itri LM. The use of epoetin alfa in chemotherapy patients: a consistent profile of efficacy and safety. Semin Oncol 2002; 29: 8187.
  • 25
    Dieterich DT. Treatment of hepatitis C and anemia in human immunodeficiency virus-infected patients. J Infect Dis 2002; 185 (Suppl 2): S128S137.
  • 26
    Quirt I, Robeson C, Lau CY, Kovacs M, Burdette-Radoux S, Dolan S, Tang SC, et al. Epoetin alfa in patients not on chemotherapy — Canadian data. Semin Oncol 2002; 29: 7580.
  • 27
    Kasper C. Recombinant human erythropoietin in the treatment of anemic patients with hematological malignancies. Ann Hematol 2001; 80: 319329.
  • 28
    Sulkowski M, Wasserman R, Brau N, et al. Once weekly recombinant human erythropoietin (Epoetin-alfa) facilitates optimal ribavirin dosing in hepatitis C virus infected patients receiving interferon alfa 2b/ribavirin therapy. AASLD, 2001, poster.
  • 29
    Schering. Dosage and administration. Package insert 2002.
  • 30
    Viscoli C. The evolution of the empirical management of fever and neutropenia in cancer patients. J Antimicrob Chemother 1998; 41 (Suppl D): 6580.
  • 31
    Viscoli C. Management of infection in cancer patients. studies of the EORTC International Antimicrobial Therapy Group (IATG). Eur J Cancer 2002; 38 (Suppl 4): S82S87.
  • 32
    Hubel K, Dale DC, Liles WC. Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colonystimulating factor, macrophage colony-stimulating factor, and interferongamma. J Infect Dis 2002; 185: 14901501.
  • 33
    Berghmans T, Paesmans M, Lafitte JJ, Mascaux C, Meert AP, Jacquy C, Burniat A, et al. Therapeutic use of granulocyte and granulocyte-macrophage colony-stimulating factors in febrile neutropenic cancer patients. A systematic review of the literature with meta-analysis. Support Care Cancer 2002; 10: 181188.
  • 34
    Higashi Y, Sakai K, Tada S, Miyase S, Nakamura T, Kamio T, Haraguchi O. Case report: agranulocytosis induced by interferon-alpha therapy for chronic hepatitis C. J Gastroenterol Hepatol 1996; 11: 10121015.
  • 35
    Van Thiel DH, Faruki H, Friedlander L, Fagiuoli S, Caraceni P, Molloy PJ, Kania RJ, et al. Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology 1995; 42: 907912.
  • 36
    Fukuda A, Kobayashi H, Teramura K, Yoshimoto S, Ohsawa N. Effects of interferon-alpha on peripheral neutrophil counts and serum granulocyte colony-stimulating factor levels in chronic hepatitis C patients. Cytokines Cell Mol Ther 2000; 6: 149154.
  • 37
    Carreno V, Martin J, Pardo M, Brotons A, Anchia P, Navas S, Fernandez M, et al. Randomized controlled trial of recombinant human granulocytemacrophage colony-stimulating factor for the treatment of chronic hepatitis c. Cytokine 2000; 12: 165170.
  • 38
    Shiffman ML, Hofmann CM, Luketic VA, Sanyal AJ. Use of granulocyte macrophage colony stimulating factor alone or in combination with interferon-alpha-2b for treatment of chronic hepatitis C. J Hepatol 1998; 28: 382389.
  • 39
    Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, Kreil A, Hofer H, Jessner W, Gangl A, et al. Rapid suppression of hematopoiesis by standard or pegylated interferon alfa. Gastroenterology 2002; 123: 141151.
  • 40
    Soza A, Everhart JE, Ghany MG, Doo E, Heller T, Promrat K, Park Y, et al. Neutropenia during combination therapy of alpha interferon and ribavirin for chronic hepatitis C. Hepatology (in press).
  • 41
    Reed WW, Diehl LF. Leukopenia, neutropenia, and reduced hemoglobin levels in healthy American blacks. Arch Intern Med 1991; 151: 501505.
  • 42
    Zdilar D, Franco-Bronson K, Buchler N, Locala JA, Younossi ZM. Hepatitis C, interferon alfa, and depression. Hepatology 2000; 31: 12071211.
  • 43
    Trask PC, Esper P, Riba M, Redman B. Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions. J Clin Oncol 2000; 18: 23162326.
  • 44
    Brown RR, Ozaki Y, Datta SP, Borden EC, Sondel PM, Malone DG. Implications of interferon-induced tryptophan catabolism in cancer, autoimmune diseases and AIDS. Adv Exp Med Biol 1991; 294: 425435.
  • 45
    Morikawa O, Sakai N, Obara H, Saito N. Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 1998; 349: 317324.
  • 46
    Bonaccorso S, Marino V, Puzella A, Pasquini M, Biondi M, Artini M, Almerighi C, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22: 8690.
  • 47
    Fontana RJ. Neuropsychiatric toxicity of antiviral treatment in chronic hepatitis C. Dig Dis 2000; 18: 107116.
  • 48
    Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, Main J, Wesnes KA, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002; 35: 433439.
  • 49
    Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 2002; 35: 440446.
  • 50
    Dwight MM, Kowdley KV, Russo JE, Ciechanowski PS, Larson AM, Katon WJ. Depression, fatigue, and functional disability in patients with chronic hepatitis C. J Psychosom Res 2000; 49: 311317.
  • 51
    Kraus MR, Schafer A, Csef H, Faller H, Mork H, Scheurlen M. Compliance with therapy in patients with chronic hepatitis C: associations with psychiatric symptoms, interpersonal problems, and mode of acquisition. Dig Dis Sci 2001; 46: 20602065.
  • 52
    Poynard T, Cacoub P, Ratziu V, Myers RP, Dezailles MH, Mercadier A, Ghillani P, et al. Fatigue in patients with chronic hepatitis C. J Viral Hepat 2002; 9: 295303.
  • 53
    Scalori A, Apale P, Panizzuti F, Mascoli N, Pioltelli P, Pozzi M, Redaelli A, et al. Depression during interferon therapy for chronic viral hepatitis: early identification of patients at risk by means of a computerized test. Eur J Gastroenterol Hepatol 2000; 12: 505509.
  • 54
    Singh N, Gayowski T, Wagener MM, Marino IR. Vulnerability to psychologic distress and depression in patients with end-stage liver disease due to hepatitis C virus. Clin Transplant 1997; 11: 406411.
  • 55
    Castera L, Zigante F, Bastie A, Buffet C, Dhumeaux D, Hardy P. Incidence of interferon alfa-induced depression in patients with chronic hepatitis C. Hepatology 2002; 35: 978979.
  • 56
    Kunkel EJ, Kim JS, Hann HW, Oyesanmi O, Menefee LA, Field HL, Lartey PL, et al. Depression in Korean immigrants with hepatitis B and related liver diseases. Psychosomatics 2000; 41: 472480.
  • 57
    Gleason OC, Yates WR, Isbell MD, Philipsen MA. An open-label trial of citalopram for major depression in patients with hepatitis C. J Clin Psychiatry 2002; 63: 194198.
  • 58
    Kraus MR, Schafer A, Faller H, Csef H, Scheurlen M. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002; 16: 10911099.
  • 59
    Mace S, Taylor D. Selective serotonin reuptake inhibitors: a review of efficacy and tolerability in depression. Expert Opin Pharmacother 2000; 1: 917933.
  • 60
    Moore JD, Bona JR. Depression and dysthymia. Med Clin North Am 2001; 85: 631644.
  • 61
    Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344: 961966.